Currently, Regulus Therapeutics Inc [RGLS] is trading at $2.80, down -2.78%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RGLS shares have gain 4.28% over the last week, with a monthly amount glided 90.48%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 21, March 2024, Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates. In a post published today on Yahoo Finance, Positive topline data from the second cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).
From an analyst’s perspective:
Regulus Therapeutics Inc [NASDAQ: RGLS] stock has seen the most recent analyst activity on March 18, 2024, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $6. Previously, B. Riley FBR Inc. started tracking the stock with Neutral rating on March 28, 2018, and set its price target to $1. On January 05, 2018, Leerink Partners initiated with a Outperform rating and assigned a price target of $2 on the stock. Chardan Capital Markets reiterated its Buy rating and decreased its price target to $2.50 on June 13, 2017. Wedbush reiterated its recommendation of a Outperform and reduced its price target to $6 on March 06, 2017. Wells Fargo downgraded its rating to Market Perform for this stock on January 30, 2017. In a note dated January 30, 2017, Needham downgraded an Hold rating on this stock.
This stock has fluctuated between a low of $0.78 and a high of $3.79 over the last 52 weeks. Regulus Therapeutics Inc [NASDAQ: RGLS] shares were valued at $2.80 at the most recent close of the market.
Analyzing the RGLS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.98, Equity is -1.09 and Total Capital is -1.4. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.62 points at the first support level, and at 2.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.94, and for the 2nd resistance point, it is at 3.09.
Regulus Therapeutics Inc [RGLS] reported earnings per share of -$0.4 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.39/share, meaning a difference of -$0.01 and a surprise factor of -2.60%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.4 per share as compared to estimates of -$0.4 per share, a difference of $0 representing a surprise of 0.00%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Regulus Therapeutics Inc [NASDAQ:RGLS] is 2.96. Also, the Quick Ratio is 2.96, while the Cash Ratio stands at 2.8.
Transactions by insiders
Recent insider trading involved Hagan Joseph P, Chief Executive Officer, that happened on Jan 18 ’24 when 14580.0 shares were sold. Chief Financial Officer, CALSADA CRISPINA completed a deal on Jan 18 ’24 to sell 5468.0 shares. Meanwhile, Sr. VP & General Counsel Aker Christopher Ray sold 5468.0 shares on Jan 18 ’24.
